Reshma Ramachandran
Datos Biográficos
| ID | 7230834 |
|---|---|
| NOMBRE | Reshma Ramachandran |
| NOMBRES | Reshma |
| APELLIDO | Ramachandran |
| FIRMA | RAMACHANDRAN R |
| AFILIACIONES | Yale University |
| ORCID | 0000-0003-3845-3606 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 6 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 6 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2021 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2025 |
| ÍNDICE H | 0 |
Public Health Implications of Legal Challenges to the FDA’s Regulation of Laboratory-Developed Tests
The case of LDTs illustrates the challenges the FDA faces when adapting regulatory frameworks in response to emerging health technologies. The outcomes of recent reforms and litigation carry substantial public health implications for both diagnostic technologies and the FDA's broader regulatory remit
Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists
This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists
Association of Covid-19 infection and Covid-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia
This study provides significant insights into the intricate correlation between ISSNHL, COVID-19 infection, and vaccination. The recognized hazard linked to infection emphasizes the significance of monitoring auditory health in COVID-19 patients
Extending the US Food and Drug Administration’s Postmarket Authorities
Under current FDA approaches to drug approval, patients, clinicians, and payers may be left with little confidence about a drug's benefit not only when it first enters the market but also for an extended period thereafter. If policy makers continue to favor earlier market access over evidentiary certainty, flexible approvals must be matched by more expansive use of postmarket safeguards, an approach possible within the FDA's existing legal author…
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
The findings of this cross-sectional study indicate that most of the drugs granted FDA accelerated approval for original indications from 2012 to 2017 lacked confirmatory trials evaluating clinical outcomes to support conversion to standard approval. Automatic coverage mandates produced substantial CMS spending for drugs with unproven clinical benefits
An Unnecessary Gift for Covid-19 Vaccines and Therapeutics
An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher Reshma Ramachandran MD, MPP, Ravi Gupta MD, and Jing Luo MD, MPH Affiliation Reshma Ramachandran is with the National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, and the Veterans Affairs Connecticut Healthcare System, West Haven, CT. Ravi Gupta is with the National Clinician Scholars Program, University of Pennsyl…
Sin obras prominentes en esta página.
An Unnecessary Gift for Covid-19 Vaccines and Therapeutics
An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher Reshma Ramachandran MD, MPP, Ravi Gupta MD, and Jing Luo MD, MPH Affiliation Reshma Ramachandran is with the National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, and the Veterans Affairs Connecticut Healthcare System, West Haven, CT. Ravi Gupta is with the National Clinician Scholars Program, University of Pennsyl…
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
The findings of this cross-sectional study indicate that most of the drugs granted FDA accelerated approval for original indications from 2012 to 2017 lacked confirmatory trials evaluating clinical outcomes to support conversion to standard approval. Automatic coverage mandates produced substantial CMS spending for drugs with unproven clinical benefits
Extending the US Food and Drug Administration’s Postmarket Authorities
Under current FDA approaches to drug approval, patients, clinicians, and payers may be left with little confidence about a drug's benefit not only when it first enters the market but also for an extended period thereafter. If policy makers continue to favor earlier market access over evidentiary certainty, flexible approvals must be matched by more expansive use of postmarket safeguards, an approach possible within the FDA's existing legal author…
Public Health Implications of Legal Challenges to the FDA’s Regulation of Laboratory-Developed Tests
The case of LDTs illustrates the challenges the FDA faces when adapting regulatory frameworks in response to emerging health technologies. The outcomes of recent reforms and litigation carry substantial public health implications for both diagnostic technologies and the FDA's broader regulatory remit
Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists
This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists
Association of Covid-19 infection and Covid-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia
This study provides significant insights into the intricate correlation between ISSNHL, COVID-19 infection, and vaccination. The recognized hazard linked to infection emphasizes the significance of monitoring auditory health in COVID-19 patients
Medicine (5 obras) · Food and drug administration (3 obras) · Biomedical Ethics and Regulation (2 obras) · Business (2 obras) · Disease (2 obras) · Drug (2 obras) · Drug approval (2 obras) · Environmental health (2 obras) · Family medicine (2 obras) · Health care (2 obras)